Editorial Commentary : Platelet‐Rich Plasma Outlasts Hyaluronic Acid for Knee Osteoarthritis, but the Product, Not the Acronym, Is the Prescription
Arthroscopy · 2026-11 · 42 (11) · 2798-2801
DOI: 10.1002/arj.70588 ↗Kurz gefasst
Editorial in der Zeitschrift Arthroscopy, online erschienen am 16.09.2026. Verfasst von Jakob Ackermann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Midwest Orthopaedics at Rush, Chicago, Illinois, U.S.A. Hauptthemen laut MEDLINE: Platelet-Rich Plasma, Osteoarthritis, Knee, Hyaluronic Acid, Viscosupplements. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Intra‐articular platelet‐rich plasma (PRP) is among the most frequently administered orthobiologic treatments for symptomatic knee osteoarthritis. PRP is not a single intervention. Preparations differ in platelet concentration, total platelet dose, leukocyte and erythrocyte content, injection volume, activation method, and injection interval, such that 2 products sharing the acronym may constitute fundamentally different biologic treatments. The randomized literature supports a small symptomatic advantage of PRP over hyaluronic acid in mild‐to‐moderate disease. That advantage appears to emerge at 12 months rather than early and is best framed as symptom modification rather than cartilage regeneration. Whether any particular formulation drives the effect is far less certain. Reported associations between platelet concentration, leukocyte enrichment, activation status, and outcome are biologically plausible, yet they are typically carried by small and heavily overlapping sets of trials in which these variables cannot be separated from one another. Platelet concentration is furthermore not equivalent to platelet dose, which is the product of concentration and injection volume. Until absolute dose, leukocyte composition, activation, and final volume are consistently reported, comparisons of high versus low concentration remain uninterpretable. In our practice, PRP and hyaluronic acid are increasingly combined for a theoretical synergistic impact because viscosupplementation and biologic signaling address distinct components of the osteoarthritic joint. Standardized product characterization, dose‐defined randomized trials, responder‐based outcomes, and improved patient selection are warranted. The acronym is not the prescription; the product is.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Midwest Orthopaedics at Rush, Chicago, Illinois, U.S.A.
Zitieren
APA
Ackermann, J., Kao, M. T., Friedman, L. R., Sassower, A., Chiampas, K., & Cole, B. J. (2026). Editorial Commentary : Platelet‐Rich Plasma Outlasts Hyaluronic Acid for Knee Osteoarthritis, but the Product, Not the Acronym, Is the Prescription. Arthroscopy, 42(11), 2798-2801. https://doi.org/10.1002/arj.70588
Vancouver
Ackermann J, Kao MT, Friedman LR, Sassower A, Chiampas K, Cole BJ. Editorial Commentary : Platelet‐Rich Plasma Outlasts Hyaluronic Acid for Knee Osteoarthritis, but the Product, Not the Acronym, Is the Prescription. Arthroscopy. 2026;42(11):2798-2801. doi:10.1002/arj.70588
BibTeX
@article{Ackermann2026,
author = {Ackermann, Jakob and Kao, Matthew T and Friedman, Lee R and Sassower, Alexis and Chiampas, Katia and Cole, Brian J},
title = {Editorial Commentary : Platelet‐Rich Plasma Outlasts Hyaluronic Acid for Knee Osteoarthritis, but the Product, Not the Acronym, Is the Prescription},
journal = {Arthroscopy},
year = {2026},
volume = {42},
number = {11},
pages = {2798--2801},
doi = {10.1002/arj.70588}
}
EUVIMED